Preeclampsia is formerly known as toxemia. Preeclampsia occurs when women have high blood pressure and possibly protein in urine during pregnancy or after delivery. Preeclampsia may result in damage to the kidneys, liver, lung, heart, or eyes, and may cause a stroke or other brain injury. Preeclampsia can lead to eclampsia, a serious condition that can have health risks for both mother and baby and in rare cases can even cause death. If preeclampsia leads to seizures, then women have eclampsia. Symptoms of preeclampsia include persistent headache, abnormal swelling in hands and face, sudden weight gain, changes in vision, and pain in the right upper abdomen. The only cure for preeclampsia is to give birth. Even after delivery, symptoms of preeclampsia can last 6 weeks or more.
Market Dynamics
Key players in the market are focusing on growth strategies such as agreements, collaborations, and product launches, which are expected to drive the market growth during the forecast period. For instance, in February 2016, Diabetomics, Inc., a privately-held global medical diagnostics company, announced that the company had entered into a licensing and distribution agreement for a clinical test with BD (Becton, Dickinson and Company), a leading global medical technology company to conduct a newly developed pregnancy specific metabolic assay for the early detection of preeclampsia and gestational diabetes. In March 2015, Siemens Healthineers AG launched two new advanced urine testing solutions for the U.S. central laboratories, namely, the CLINITEK Novus Automated Urine Chemistry Analyzer and the CLINITEK AUWi PRO Automated Urine Workstation.
Key features of the study:
- This report provides in-depth analysis of the global preeclampsia diagnostics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global preeclampsia diagnostics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global preeclampsia diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Preeclampsia Diagnostics Market.
Detailed Segmentation:
- Global Preeclampsia Diagnostics Market, By Test Type:
- Blood Tests
- Urine Analysis
- Others
- Global Preeclampsia Diagnostics Market, By Product Type:
- Global Preeclampsia Diagnostics Market, By End User:
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- Global Preeclampsia Diagnostics Market, By Region:
- North America
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- By Country
- Latin America
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Test Type
- Blood Tests
- Urine Analysis
- Others
- Product Type
- End User
- Hospital
- Specialty Clinics
- Diagnostic Centers
- Others
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Diabetomics, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc.
- Hoffmann-La Roche Ltd.
- PerkinElmer Inc.
- Siemens Healthineers AG
- DRG INSTRUMENTS GMBH
- Metabolomic Diagnostics Ltd.
- Sera Prognostics
- MOMM Diagnostics
- Miraculins Inc.
“*” marked represents similar segmentation in other categories in the respective section
